Gene Therapy in Cardiac Arrhythmias

Praveen, S.V and Francis, Johnson and Venugopal, K (2006) Gene Therapy in Cardiac Arrhythmias. [Journal (Paginated)]

Full text available as:



Gene therapy has progressed from a dream to a bedside reality in quite a few human diseases. From its first application in adenosine deaminase deficiency, through the years, its application has evolved to vascular angiogenesis and cardiac arrhythmias. Gene based biological pacemakers using viral vectors or mesenchymal cells tested in animal models hold much promise. Induction of pacemaker activity within the left bundle branch can provide stable heart rates. Genetic modification of the AV node mimicking beta blockade can be therapeutic in the management of atrial fibrillation. G protein overexpression to modify the AV node also is experimental. Modification and expression of potassium channel genes altering the delayed rectifier potassium currents may permit better management of congenital long QT syndromes. Arrhythmias in a failing heart are due to abnormal calcium cycling. Potential targets for genetic modulation include the sarcoplasmic reticulum calcium pump, calsequestrin and sodium calcium exchanger.Lastly the ethical concerns need to be addressed.

Item Type:Journal (Paginated)
Keywords:Gene therapy; biological pacemakers; AV node modification; long QT syndromes; sarcoplasmic reticulum calcium pump
Subjects:JOURNALS > Indian Pacing and Electrophysiology Journal
ID Code:4805
Deposited By:Indian Pacing and Electrophysiology, Journal
Deposited On:01 Apr 2006
Last Modified:11 Mar 2011 08:56

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. Members of the Sicilian gambit. New approaches to antiarrhythmic therapy, part II;Circulation 2001;104: 2990-2994.

2. Lee ER, Marshall J, Siegel CS, et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther 1996; 7: 1701­17.

3. Armentano D, Zabner J, Sacks C, et al. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997;71:2408­16.

4. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet. 2000:355;213-222.

5. Smith AE. Gene therapy--where are we? Lancet. 1999;354 Suppl 1:SI1-4.

6. Labhasetwar V, Bonadio J, Goldstein S, Chen W, Levy RJ. A DNA controlled-release coating for gene transfer: transfection in skeletal and cardiac muscle. J Pharm Sci. 1998 ;87:1347-50.

7. Donahue JK, Kikkawa K, Johns DC, Marban E, Lawrence JH. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci U S A. 1997 ;94:4664-8.

8. Rosen MR, Robinson RB, Brink P, Cohen IS; Anat Rec A Discov Mol Cell Evol Biol. 2004;280:1046-52.

9. Rajesh G, Francis J. Biological Pacemakers. Indian Pacing Electrophysiol J. 2006; 6:1-5.

10. Rosen MR, Brink PR, Cohen IS, Robinson RB. Genes, stem cells and biological pacemakers Cardiovasc Res. 2004;64:12-23.

11. Qu J, Plotnikov AN, Sosunov EA et al. Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation. 2004;109:506-12.

12. Glenn CM, Pogwizd SM. Gene therapy to develop a genetically engineered cardiac pacemaker. J Cardiovasc Nurs. 2003;18:330-6.

13. Donahue JK, Heldman AW et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med. 2000;6:1395-8.

14. Bauer A, McDonald AD, Nasir K, Peller L, Rade JJ, Miller JM, Heldman AW, Donahue JK. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation. 2004 ;110:3115-20.

15. Fabritz L, Kirchhof P, Fortmuller L, Auchampach JA, Baba HA, Breithardt G, Neumann J, Boknik P, Schmitz W. Gene dose-dependent atrial arrhythmias, heart block, and brady-cardiomyopathy in mice overexpressing A(3) adenosine receptors. Cardiovasc Res. 2004;62:500-8

16. Murata M, Cingolani E, McDonald AD, Donahue JK, Marban E. Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. Circ Res. 2004;95:398-405.

17. Burton DY, Song C, Fishbein I, Hazelwood S, Li Q, DeFelice S, Connolly JM, Perlstein I, Coulter DA, Levy RJ. The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specific arrhythmia gene therapy: in vitro and in vivo feasibility studies. Human Gene Ther; 2003;14:907-22.

18. Mazhari R, Nuss HB, Armoundas AA, Winslow RL, Marban E. Ectopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT interval. J Clin Invest. 2002;109:1083-90.

19. Ennis IL, Li RA , Murphy AM, Marban E, Nuss HB. Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility. J Clin Invest. 2002;109:393-400.

20. Francis J, Sankar V, Krishnan Nair V, Priori SG. Catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2005;2:550-4.

21. Hobai IA, O'Rourke B. The potential of Na+/Ca2+ exchange blockers in the treatment of cardiac disease. Expert Opin Investig Drugs. 2004;13:653-64.

22. Nuss HB, Johns DC, Kaab S, Tomaselli GF, Kass D, Lawrence JH, Marban E. Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene transfer: a prototype for gene therapy for disorders of cardiac excitability and contractility. Gene Ther. 1996;3:900-12.

23. HuaF, JohnsDC, Gilmour RF Jr. Suppression of electrical alternans by overexpression of HERG in canine ventricular myocytes. Am J Physiol Heart Circ Physiol. 2004;286:H2342-51.

24. Baker AH. Designing gene delivery vectors for cardiovascular gene therapy. Progs biophys mol 2004;84; 279-99.

25. Beck C, Uramoto H , Jan Boren,Levent M Akyurek. Tissue specific targeting for cardiovascular gene transfer. Potentials vectors and future challenges. Curr Gene Therapy. 2004;4;457-67.

26. Palffy R, Gadlik R ,J Hodosy, M Behuliak. Bacteria in gene therapy; Bactofection versus alternative gene therapy. Gene Therapy 2006(13) 101-105.


Repository Staff Only: item control page